CDRE Cadre (CDRE) Insider Trading, Ownership & Congress Trades
Medical Devices · Orthopedic, prosthetic & surgical appliances & supplies · CIK 0001860543
Congress · 1Form 144 · 3
Insider buyers, 180 days
0
Funds added, last quarter
94
13F, latest reported quarter
Conversions, 180 days
2
Codes C/M, not in net · $1.9M priced
What the filings say about CDRE
Insiders, 180 days
-$18.1M net sold
2 sellers · 0% of sales under a 10b5-1 plan
Congress, 1 year
1 bought · 0 sold
Latest: purchase, 2026-06-30
Planned sales (Form 144), 90 days
$9.6M
3 notices
Cadre insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
Over the last 180 days, Cadre Holdings, Inc. insiders sold a net $18.1M of stock across 123 Form 4 purchases and sales, with no insider buying. Source: SEC Form 4 filings, as of 2026-10-27.
Insider
Filed
Shares
Value
Since filing
Context
- 67 earlier Form 4 trades (code P or S) here by this insider (67 sales), the last on Aug 24, 2026.
- The trade is 0.6% of the 9,461,694 shares held after it.
- 1 other insider sold within 30 days.
- 94 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: CEO AND CHAIRMAN KANDERS WARREN B sold about $1.7M of CDRE on Aug 25, 2026; 1 other insider sold within 30 days and 94 funds added in the latest 13F quarter.Context
- 67 earlier Form 4 trades (code P or S) here by this insider (67 sales), the last on Aug 24, 2026.
- The trade is 0.5% of the 9,417,039 shares held after it.
- 1 other insider sold within 30 days.
- 94 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: CEO AND CHAIRMAN KANDERS WARREN B sold about $1.4M of CDRE on Aug 25, 2026; 1 other insider sold within 30 days and 94 funds added in the latest 13F quarter.Context
- 65 earlier Form 4 trades (code P or S) here by this insider (65 sales), the last on Jun 22, 2026.
- The trade is 0.7% of the 9,551,608 shares held after it.
- 1 other insider sold within 30 days.
- 94 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: CEO AND CHAIRMAN KANDERS WARREN B sold about $2.2M of CDRE on Aug 24, 2026; 1 other insider sold within 30 days and 94 funds added in the latest 13F quarter.Context
- 65 earlier Form 4 trades (code P or S) here by this insider (65 sales), the last on Jun 22, 2026.
- The trade is 0.4% of the 9,517,039 shares held after it.
- 1 other insider sold within 30 days.
- 94 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: CEO AND CHAIRMAN KANDERS WARREN B sold about $1.2M of CDRE on Aug 24, 2026; 1 other insider sold within 30 days and 94 funds added in the latest 13F quarter.Context
- 13 earlier Form 4 trades (code P or S) here by this insider (1 buy, 12 sales), the last on Dec 10, 2025.
- The trade is 0.1% of the 153,719 shares held after it.
- 1 other insider sold within 30 days.
- 94 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: PRESIDENT Williams Brad sold about $3.6K of CDRE on Aug 17, 2026; 1 other insider sold within 30 days and 94 funds added in the latest 13F quarter.123 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
net -$18.1M over 180 days
-$9.5M over 90 days · -$15.1M of it by a 10%+ holder
below 91% of Medical Devices
Congress
1 member bought in the last year
the lowest in Medical Devices
Funds
94 funds bought in last quarter
more than 62% of Medical Devices
Revenue
+7.5% year over year
below 56% of Medical Devices
Margin
7.2% net margin
more than 77% of Medical Devices
Buybacks
no share repurchases reported
Short interest
7.0% of the float short (float per yahoo 2026-10-26) · 3.3 days to cover · settled 2026-09-30
more than 61% of Medical Devices
What changed in the last 30 days
Nothing new filed in the last 30 days
Watch CDRE
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-26.2%12M
Insider sellForm 144 (planned sale)
Indexed to 100, dividend-adjusted, not a price chart.
When a name files heavily, the largest trades are drawn first.
Who owns CDRE: institutional holders (13F)
13F holdings, latest reported quarter
2,936,878 sh
$83.7M
2,868,664 sh
$81.8M
2,738,373 sh
$78.1M
2,475,623 sh
$70.6M
1,949,734 sh
$55.6M
Congress trades in CDRE
STOCK Act disclosures, US House only, filed up to 45 days after the trade
Bought 2026-06-30 · disclosed 2 days later
$1,001 - $15,000
Bought 2026-03-16 · disclosed 22 days later
$1,001 - $15,000
Bought 2025-06-11 · disclosed 29 days later
$1,001 - $15,000
Sold 2025-04-17 · disclosed 27 days later
$1,001 - $15,000
Bought 2025-01-27 · disclosed 14 days later
$1,001 - $15,000
Activist and 5% holders (13D/13G)
No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.
CDRE planned insider sales (Form 144)
Notice of intent to sell, filed before any sale
Warren B. Kanders
Filed 2026-08-25
$3.2M
Warren B. Kanders
Filed 2026-08-24
$3.3M
Brad Williams
Filed 2026-08-17
$3.0M
CDRE mutual fund holders (N-PORT)
Funds ranked by the share of their own portfolio in this stock (N-PORT).
Baird Equity Opportunity Fund
$2.8M position · as of 2026-06-30
3.6%
Cromwell Greenspring Mid Cap Fund
$3.3M position · as of 2026-06-30
2.4%
Reinhart Genesis PMV Fund
$16.2M position · as of 2026-05-31
2.3%
CRAWFORD SMALL CAP DIVIDEND FUND
$5.6M position · as of 2026-06-30
1.5%
Brown Advisory Small-Cap Fundamental Value Fund
$15.0M position · as of 2026-06-30
1.2%
AMG GW&K Small Cap Growth Fund
$2.4M position · as of 2026-07-31
1.2%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M ·
% is the share of the fund's own portfolio
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
Insiders have filed to sell, before selling.
The record shows a net $18.1M sold by insiders over 180 days, 94 funds added last quarter, 1 House member(s) bought in 12 months, disclosed weeks after the trade, $9.6M in planned Form 144 sales. Each figure is a federal filing, dated the day it went public.
CDRE financials
Revenue growth
+7.5%
XBRL, annual
Net margin
7.2%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$685.6M
four quarters, 2025-07-01 to 2026-06-30
Revenue, TTM CDRE
| FY Dec 2025 | $610.3M |
| FY Dec 2024 | $567.6M |
| FY Dec 2023 | $482.5M |
| FY Dec 2022 | $457.8M |
| FY Dec 2021 | $427.3M |
| Jun 2026 | $207.1M |
| Mar 2026 | $155.4M |
| Dec 2025 | $167.2M |
| Sep 2025 | $155.9M |
| Jun 2025 | $157.1M |
| Mar 2025 | $130.1M |
| Dec 2024 | $176.0M |
| Sep 2024 | $109.4M |
At each fiscal year end
Single quarter
Net margin, TTM
+5.3%
net income over revenue, 2025-07-01 to 2026-06-30
Net margin, TTM CDRE
| FY Dec 2025 | +7.2% |
| FY Dec 2024 | +6.4% |
| FY Dec 2023 | +8.0% |
| FY Dec 2022 | +1.3% |
| FY Dec 2021 | +3.0% |
| Jun 2026 | +5.5% |
| Mar 2026 | +1.3% |
| Dec 2025 | +7.0% |
| Sep 2025 | +7.0% |
| Jun 2025 | +7.8% |
| Mar 2025 | +7.1% |
| Dec 2024 | +7.4% |
| Sep 2024 | +3.3% |
At each fiscal year end
Single quarter
Free cash flow, TTM
$78.1M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Free cash flow, TTM CDRE
| FY Dec 2025 | $56.8M |
| FY Dec 2024 | $26.1M |
| FY Dec 2023 | $66.5M |
| FY Dec 2022 | $41.9M |
| FY Dec 2021 | $37.3M |
| Jun 2026 | $18.7M |
| Mar 2026 | $19.8M |
| Dec 2025 | $18.0M |
| Sep 2025 | $21.6M |
| Jun 2025 | $1.2M |
| Mar 2025 | $16.1M |
| Dec 2024 | $22.4M |
| Sep 2024 | -$6.2M |
At each fiscal year end
Single quarter
Debt to equity
1.08x
long-term 2026-06-30 plus current 2026-06-30; equity 2026-06-30
Debt to equity CDRE
| FY Dec 2025 | 0.97x |
| FY Dec 2024 | 0.72x |
| FY Dec 2023 | 0.71x |
| FY Dec 2022 | 0.90x |
| FY Dec 2021 | 1.80x |
| Jun 2026 | 1.08x |
| Mar 2026 | 1.09x |
| Dec 2025 | 0.97x |
| Sep 2025 | 0.91x |
| Jun 2025 | 0.95x |
| Mar 2025 | 0.69x |
| Dec 2024 | 0.72x |
| Sep 2024 | 0.69x |
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
0.24x
TTM operating cash flow over long-term 2026-06-30 plus current 2026-06-30
Cash flow to debt CDRE
| FY Dec 2025 | 0.21x |
| FY Dec 2024 | 0.14x |
| FY Dec 2023 | 0.52x |
| FY Dec 2022 | 0.31x |
| FY Dec 2021 | 0.25x |
| Jun 2026 | 0.24x |
| Mar 2026 | 0.19x |
| Dec 2025 | 0.21x |
| Sep 2025 | 0.21x |
| Jun 2025 | 0.12x |
| Mar 2025 | 0.21x |
| Dec 2024 | 0.14x |
| Sep 2024 | 0.17x |
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
+10.6%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on equity CDRE
| FY Dec 2025 | +14.0% |
| FY Dec 2024 | +14.2% |
| FY Dec 2023 | +21.3% |
| FY Dec 2022 | +4.6% |
| FY Dec 2021 | +26.0% |
| Jun 2026 | +10.6% |
| Mar 2026 | +11.3% |
| Dec 2025 | +14.0% |
| Sep 2025 | +14.2% |
| Jun 2025 | +12.1% |
| Mar 2025 | +13.1% |
| Dec 2024 | +14.2% |
| Sep 2024 | +13.4% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
+4.2%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets CDRE
| FY Dec 2025 | +6.2% |
| FY Dec 2024 | +6.7% |
| FY Dec 2023 | +9.4% |
| FY Dec 2022 | +1.7% |
| FY Dec 2021 | +4.3% |
| Jun 2026 | +4.2% |
| Mar 2026 | +4.8% |
| Dec 2025 | +6.2% |
| Sep 2025 | +6.4% |
| Jun 2025 | +5.4% |
| Mar 2025 | +6.1% |
| Dec 2024 | +6.7% |
| Sep 2024 | +6.3% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
+7.2%
operating income after a 31.0% effective tax rate, over long-term 2026-06-30 plus current 2026-06-30 plus average of 2025-06-30 and 2026-06-30 minus cash
Return on invested capital CDRE
| FY Dec 2025 | +9.6% |
| FY Dec 2024 | +12.6% |
| FY Dec 2023 | +12.8% |
| FY Dec 2022 | +3.7% |
| FY Dec 2021 | +16.4% |
| Jun 2026 | +7.2% |
| Mar 2026 | +6.6% |
| Dec 2025 | +9.6% |
| Sep 2025 | +10.1% |
| Jun 2025 | +8.3% |
| Mar 2025 | +11.6% |
| Dec 2024 | +12.6% |
| Sep 2024 | +8.2% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
+9.6%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
Return on capital employed CDRE
| FY Dec 2025 | +11.0% |
| FY Dec 2024 | +14.9% |
| FY Dec 2023 | +17.4% |
| FY Dec 2022 | +6.1% |
| FY Dec 2021 | +22.6% |
| Jun 2026 | +9.6% |
| Mar 2026 | +9.4% |
| Dec 2025 | +11.0% |
| Sep 2025 | +12.6% |
| Jun 2025 | +10.4% |
| Mar 2025 | +12.8% |
| Dec 2024 | +14.9% |
| Sep 2024 | +11.7% |
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
37.02x
close 2026-10-23 over four quarters of diluted EPS, 2025-07-01 to 2026-06-30
P/E, trailing CDRE
| FY Dec 2025 | 39.65x |
| FY Dec 2024 | 35.89x |
| FY Dec 2023 | 32.25x |
| FY Dec 2022 | 154.92x |
| FY Dec 2021 | 56.49x |
| Jun 2026 | 35.20x |
| Mar 2026 | 36.09x |
| Dec 2025 | 39.65x |
| Sep 2025 | 32.60x |
| Jun 2025 | 33.88x |
| Mar 2025 | 31.17x |
| Dec 2024 | 35.89x |
| Sep 2024 | 45.72x |
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
$1.6B
market value at close 2026-10-23 on 2026-07-31 shares, plus long-term 2026-06-30 plus current 2026-06-30, minus cash 2026-06-30
Enterprise value CDRE
| FY Dec 2025 | $1.8B |
| FY Dec 2024 | $1.4B |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | $1.5B |
| Mar 2026 | $1.6B |
| Dec 2025 | $1.8B |
| Sep 2025 | $1.7B |
| Jun 2025 | $1.5B |
| Mar 2025 | $1.3B |
| Dec 2024 | $1.4B |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
+6.1%
TTM free cash flow over market value at close 2026-10-23
FCF yield CDRE
| FY Dec 2025 | +3.4% |
| FY Dec 2024 | +2.0% |
| FY Dec 2023 | +5.4% |
| FY Dec 2022 | +5.6% |
| FY Dec 2021 | +4.3% |
| Jun 2026 | +6.4% |
| Mar 2026 | +4.6% |
| Dec 2025 | +3.4% |
| Sep 2025 | +4.1% |
| Jun 2025 | +2.6% |
| Mar 2025 | +3.4% |
| Dec 2024 | +2.0% |
| Sep 2024 | +1.8% |
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
n/a
trailing EPS growth -14%, PEG needs growth
PEG, trailing CDRE
| FY Dec 2025 | 2.75x |
| FY Dec 2024 | n/a |
| FY Dec 2023 | 0.05x |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | 2.75x |
| Sep 2025 | 0.93x |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-23. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
| 2025-12 | 2024-12 | 2023-12 | 2022-12 | |
|---|---|---|---|---|
| Revenue | $610.3M | $567.6M | $482.5M | $457.8M |
| Gross profit | $259.6M | $233.5M | $200.7M | $175.7M |
| Operating income | $67.4M | $66.8M | $56.5M | $16.7M |
| Net income | $44.1M | $36.1M | $38.6M | $5.8M |
| EPS (diluted) | 1.02 | 0.90 | 1.02 | 0.16 |
| Operating cash flow | $63.7M | $31.8M | $73.2M | $46.4M |
| Cash | $122.9M | $124.9M | n/a | n/a |
| Long-term debt | $291.0M | $211.8M | $127.8M | $137.5M |
| Dividends paid | $15.4M | $13.9M | $12.0M | $11.5M |
SEC XBRL, fiscal years, as known on 2026-10-27
CDRE Stock Sonar score 6/7 axes
Find similar shapesCompareCDRE ranks highest on growth (72nd percentile) and profitability (68th), and lowest on insider conviction (4th), among Medical Devices peers.
6 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
CDRE filings, in plain words
Are Cadre insiders buying or selling CDRE?
In the 180 days to 2026-10-27, Cadre insiders were net sellers, a net $18.1M across purchases and sales reported on Form 4, by 2 sellers.
Have members of Congress traded CDRE?
Yes. In the year to 2026-10-27, 1 House member disclosed buying CDRE and 0 House members disclosed selling it; the latest on record is a purchase by Gilbert Cisneros dated 2026-06-30.
Are there planned insider sales of CDRE?
Yes. 3 Form 144 notices of planned insider sales were filed in the 90 days to 2026-10-27, covering $9.6M of stock; the latest, by Warren B. Kanders, was filed 2026-08-25.
Read the full summary
In the 180 days to 2026-10-27, Cadre insiders were net sellers of CDRE, a net $18.1M across purchases and sales reported on Form 4 by 2 sellers. Most of that figure, $15.1M, came from a holder of 10% or more rather than an officer or director. None of the 11 insider sales was flagged as made under a Rule 10b5-1 plan. In the year to 2026-10-27, 1 member of Congress disclosed buying CDRE and 0 members disclosed selling it; the latest on record is a purchase by Gilbert Cisneros dated 2026-06-30. Insiders filed 3 Form 144 notices of intent to sell in the 90 days to 2026-10-27, covering $9.6M of stock. Each figure is counted from SEC and House filings as of 2026-10-27, dated the day the filing was made public.
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
